Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > 431 million + 27 million

<< Previous

Bullboard Posts

Next >>

Comment by GoldenInvestoron Aug 17, 2020 3:48pm

74 Views

Post# 31419486

RE:RE:431 million + 27 million

Terrific! I just did a quick Google search for canada population.

thats what I got, but more current #'s are better.

thanks.

your comments have been discussed here a lot before, & are understandable.

Hiwever, now GUD has grown a lot via GBT acquisition & will be exciting to see it evolve & grow.

it may have taken a long time, however, as previously noted, PALADIN, share price growth was stagnant for a long time before liftoff.

& now GUD, seems to have added a lot of potential for sales growth & sales channels with South Anerica.

<< Previous

Bullboard Posts

Next >>

Why Roth Capital Partners gives GameSquare a 'buy' rating